Panthera Biopartners Joins AMRC to Help Shape Global Clinical Trial Quality

Panthera Biopartners, the UK’s largest independent Site Management Organisation (SMO), has joined the Association of Multisite Research Corporations (AMRC), a trade body focused on advancing the value of multisite clinical research organisations.

AMRC was founded to promote the benefits of the multisite model and to strengthen understanding of its role among sponsors, CROs, policymakers and regulators. The association acts as a link between multisite networks, pharmaceutical companies and regulatory stakeholders, helping ensure the capabilities of large multisite organisations are recognised and effectively used.

For Panthera, membership supports closer industry collaboration, broader advocacy and a stronger role in shaping the future of clinical research.

Panthera CEO Stuart Young said the company was proud to join AMRC at a time when sponsors are seeking deeper and more strategic partnerships with research sites. He said multisite organisations now play an important role in defining high-quality trial delivery, not only through speed and scale, but through consistent and measurable standards across geographies.

By joining AMRC, Panthera underlines its commitment to innovation, operational excellence and partnership, while supporting the delivery of high-quality clinical research worldwide.